This website is intended for US Healthcare Professionals.
This website is intended for US Healthcare Professionals.
REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.
REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
REBLOZYL (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Request a Rep
Balanced across study arms in pivotal Phase 3 COMMANDS trial1
Disease Characteristic | REBLOZYL (n=178) |
Epoetin Alfa (n=178) |
---|---|---|
Hemoglobin (g/dL) | ||
Median (min, max) | 7.80 (4.7, 9.2) | 7.80 (4.5, 10.2) |
Serum EPO (U/L) | ||
Median (min, max) | 78.7 (7.8, 495.8) | 85.9 (4.6, 462.5) |
IPSS-R risk classification at baseline – n (%) | ||
Very low | 16 (9.0) | 17 (9.6) |
Low | 126 (70.8) | 131 (73.6) |
Intermediate | 34 (19.1) | 28 (15.7) |
High | 1 (0.6) | 0 (0) |
Missing | 1 (0.6) | 2 (1.1) |
Ring sideroblast status (per WHO criteria) – n (%) | ||
RS-positive | 130 (73.0) | 128 (71.9) |
RS-negative | 48 (27.0) | 49 (27.5) |
Missing | 0 (0) | 1 (0.6) |
SF3B1 mutation status – n (%) | ||
Mutated | 111 (62.4) | 99 (55.6) |
Non-mutated | 65 (36.5) | 72 (40.4) |
Missing | 2 (1.1) | 7 (3.9) |
EPO=erythropoietin; RBC=red blood cell; RS=ring sideroblasts; WHO=World Health Organization.